CRISPR Therapeutics (CRSP) has been back in focus after its stock moved higher on continued progress across its gene editing pipeline, including the commercial rollout of Casgevy and updates on newer programs.

CRISPR Therapeutics’ recent 9.35% 1 day share price return and 8.72% 30 day share price return, taking the stock to US$56.95, reflects renewed interest following Casgevy’s rollout and fresh updates across its gene editing programs. A 47.65% 1 year total shareholder return contrasts with weaker multi year total shareholder returns, suggesting momentum has recently been rebuilding.

If you are looking beyond a single stock in gene editing, this could be a good moment to see what else is gaining attention in healthcare related AI, starting with 40 healthcare AI stocks.

With CRISPR Therapeutics now profitable on consensus estimates yet still loss making on reported net income, and trading below some analyst targets, the key question is whether there is genuine upside potential or if the current price already reflects expectations for future growth.

Price-to-Book of 3x: Is it justified?

On simple metrics, CRISPR Therapeutics looks expensive compared to the broader US Biotechs industry, yet cheaper than closer peers, which sends a mixed signal at $56.95.

The key yardstick here is the P/B ratio, which compares the company’s market value to its book value of equity. CRISPR Therapeutics trades on a P/B of 3x, versus a 2.5x average for the US Biotechs industry, but below a 7.4x peer group average.

For a business that is still reporting losses and does not yet have meaningful revenue at $4 million, a premium to the wider industry suggests the market is placing value on the gene editing pipeline and revenue growth forecasts, rather than current earnings. At the same time, the discount to the peer average P/B indicates investors are not assigning as rich a valuation as they are to some closer biotech comparables.

Against this backdrop, Simply Wall St’s DCF model provides an internal estimate of future cash flow value of $182.56 per share, which is above the current $56.95 price and implies CRISPR Therapeutics is trading 68.8% below that internal fair value estimate. There is a sizable difference between the current share price and that model output, and if the revenue growth forecasts of 64.8% per year occur as projected in the model, it indicates the market could reassess how it prices the company’s future cash flows.

Result: Price-to-book of 3x (UNDERVALUED)

However, there are still clear risks, including ongoing net losses of $568.534 million and uncertainty around how quickly the broader gene editing portfolio can translate into meaningful revenue.

Another angle on value

CRISPR Therapeutics trades on a P/B of 3x, which looks expensive next to the US Biotechs industry at 2.5x but cheaper than peers at 7.4x. That split points to both valuation risk and potential opportunity, so it is worth considering which side of the trade you are more comfortable owning.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment mixed across risks and rewards, do not wait for others to tell you what to think. Review the data, stress test your own thesis, then weigh the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop with one stock. Use focused stock lists to spot opportunities before everyone else catches on.

• Target potential value opportunities early by scanning 47 high quality undervalued stocks that pair stronger fundamentals with prices that still look conservative.
• Prioritise resilience by reviewing 65 resilient stocks with low risk scores that score well on stability and may help smooth out the bumpier parts of your portfolio.
• Stay ahead of the crowd by checking screener containing 22 high quality undiscovered gems before they reach more investors’ radars and pricing adjusts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.